Repurposing as a strategy for orphan drug development, evidence from European approvals

Bibliography

• NCATS (National Center for Advancing Translational Science). Available from: http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/rescue-repurpose.html
   Google Scholar
• Roche, Roche and the Broad Institute Collaborate to Identify Novel Uses for Advanced Compounds, Press Release 28 November 2012
   Google Scholar
• Cavalla D. Predictive methods in drug repurposing: gold mine or just a bigger haystack? Drug Discov Today 2012;6446(12):00432-1
   Google Scholar
• Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 2011;16(7-8):298-310
   PubMed Web of Science ®Google Scholar
• Phillips MI. Big Pharma's new model in orphan drugs and rare diseases. Expert Opin Orphan Drugs 2013;1:1-3
   Web of Science ®Google Scholar
• Norman P. Drug discovery for rare diseases. Scrip Insights, Informa, London; 2012
   Google Scholar
• Norman P. Orphan drug approvals in Europe since 2001; an analysis by indication. Expert Opin Orphan Drugs 2013;1:131-9
   Web of Science ®Google Scholar
• Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984;36(5):661-9
   PubMed Web of Science ®Google Scholar
• Weiss AJ, Stambaugh JE, Mastrangelo MJ. Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother Rep 1972;56(3):413-19
   PubMedGoogle Scholar
• Bolton BH, Kaung DT, Lawton RL, Woods LA. Hydroxyurea (NSC-32065)– a phase I study. Cancer Chemother Rep 1964;39:47-51
   Google Scholar
• Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89(9):3354-60
   PubMed Web of Science ®Google Scholar
• Guffon N, Vianey-Saban C, Bourgeois J, et al. A new neonatal case of N-acetylglutamate synthase deficiency treated by carbamylglutamate. J Inherit Metab Dis 1995;18(1):61-5
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998;132(4):264-78
   PubMed Web of Science ®Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321(23):1567-71
   Google Scholar
• Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res 1981;5(6):453-62
   PubMed Web of Science ®Google Scholar
• Simoens S, Picavet E, Cassiman D, Dooms M. (2012). Orphan diseases: which ones do we adopt? BMJ 2008;337:a1225
   Google Scholar
• Akbary AM, Wirth KJ, Schölkens BA. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 1996;33(1-3):238-42
   Google Scholar
• Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010;104(3):193-204
   PubMed Web of Science ®Google Scholar
• Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107(6):529-37
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57
   PubMed Web of Science ®Google Scholar
• Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85(2-3):195-7
   PubMed Web of Science ®Google Scholar
• Ramos E, Aróstegui JI, Campuzano S, et al. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology (Oxford) 2005;44(8):1072-3
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13(6):R202
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002 Jul;1(7):493-502
   PubMed Web of Science ®Google Scholar
• Ciba Geigy AG. Pyrimidine derivatives and process for their preparation. EP0564409A; 1993
   Google Scholar
• Clemons PA. Complex phenotypic assays in high-throughput screening. Curr Opin Chem Biol 2004;8(3):334-8
   PubMed Web of Science ®Google Scholar
• Higgs G. Molecular genetics: the Emperor's clothes of drug discovery? Drug Discov Today 2004;9(17):727-9
   Google Scholar
• Guiguemde WA, Shelat AA, Garcia-Bustos JF, et al. Global phenotypic screening for antimalarials. Chem Biol 2012;19(1):116-29
   Google Scholar
• Beaulieu CL, Samuels ME, Ekins S, et al. A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis 2012;7:39
   Google Scholar